{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:22:22Z","timestamp":1791256942501,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.leukres.2006.05.018","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T22:52:09Z","timestamp":1152226329000},"page":"559-562","source":"Crossref","is-referenced-by-count":23,"title":["Bortezomib is an effective agent for MDS\/MPD syndrome with 5q\u2212 anomaly and thrombocytosis"],"prefix":"10.1016","volume":"31","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Verrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Banti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Kaloutsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lazaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Zervas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2006.05.018_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-4608(96)00350-0","article-title":"5q\u2212, twenty-five years later: a synopsis","volume":"94","author":"Van den Berghe","year":"1997","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.leukres.2006.05.018_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1096-8652(199606)52:2<124::AID-AJH2830520204>3.0.CO;2-C","article-title":"Possible cytokine mechanism of increased megakaryocytic proliferation in 5q\u2212 syndrome","volume":"52","author":"Ustundag","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2006.05.018_bib3","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V84.10.3253.3253","article-title":"The 5q\u2212 syndrome","volume":"84","author":"Boultwood","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.05.018_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V81.3.624.624","article-title":"Human interleukin-4 inhibits proliferation of megakaryocyte progenitor cells in culture","volume":"81","author":"Sonoda","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.05.018_bib5","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.05.018_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/jcpa.1998.0290","article-title":"Occlusion of pulmonary vessels by megakaryocytes after treatment with tumour necrosis factor-alpha (TNF-alpha)","volume":"120","author":"Sulkowski","year":"1999","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.leukres.2006.05.018_bib7","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2006.05.018_bib8","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2006.05.018_bib9","first-page":"1534","article-title":"Effect of proteasome inhibition by bortezomib on tumor necrosis factor-alpha (TNF-\u03b1) and apoptosis in patients with myelodysplastic syndromes (MDS)","volume":"106","author":"Shetty","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.05.018_bib10","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.V98.10.2935","article-title":"Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution","volume":"98","author":"Nosslinger","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.05.018_bib11","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.05.018_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.leukres.2004.07.014","article-title":"A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals","volume":"29","author":"Cabello","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2006.05.018_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0165-4608(92)90376-J","article-title":"Deletion of the long arm of chromosome 5 in essential thrombocythemia","volume":"61","author":"Reis","year":"1992","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.leukres.2006.05.018_bib14","first-page":"517","article-title":"5q\u2212 syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders?","volume":"9","author":"Koike","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2006.05.018_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/(SICI)1096-8652(200006)64:2<120::AID-AJH9>3.0.CO;2-M","article-title":"5q\u2212 syndrome presenting chronic myeloproliferative disorders-like manifestation: a case report","volume":"64","author":"Takahashi","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2006.05.018_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"57","author":"Richardson","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.leukres.2006.05.018_bib17","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2005.04.0824","article-title":"Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma","volume":"24","author":"Dubois","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2006.05.018_bib18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2006.05.018_bib19","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2006.05.018_bib20","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2005-05-1989","article-title":"NF-kappa B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome","volume":"107","author":"Braun","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.05.018_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000065722","article-title":"Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome","volume":"63","author":"Hsu","year":"2002","journal-title":"Oncology"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606002050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606002050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T07:40:10Z","timestamp":1587022810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212606002050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0145212606002050"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2006.05.018","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}